BMRN - Biomarin Pharmaceutical - Stock Forecast

Healthcare - Sector
Coverage Profile Stock analysts Price Targets & Ratings Chart Insider Trading

BMRN is currently covered by 21 analysts with an average price target of $88.71. This is a potential upside of $30.76 (35.41%) from yesterday's end of day stock price of $65.51.

Biomarin Pharmaceutical's activity chart (see below) currently has 499 price targets and 376 ratings on display. The stock rating distribution of BMRN is 21.95% HOLD and 78.05% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 45.95% with an average time for these price targets to be met of 345.13 days.

Highest price target for BMRN is $124, Lowest price target is $55, average price target is $88.71.

Most recent stock forecast was given by AKASH TEWARI from JEFFERIES on 31-Aug-2026.

Overview

BioMarin Pharmaceutical . is a biotechnology company that specializes in the development and commercialization of therapies for rare and life-threatening diseases. The company’s main focus is on the development of therapies for patients with genetic disorders.

Pipeline

BioMarin’s commercial products include Vimizim, Naglazyme, Kuvan, Palynziq, Brineura, Voxzogo, and Aldurazyme, which are used for the treatment of various rare diseases such as mucopolysaccharidosis, phenylketonuria, and ceroid lipofuscinosis.

The company is also developing gene therapies for hemophilia A, Hereditary Angioedema, and primary hyperoxaluria.

Collaborations

BioMarin has license and collaboration agreements with other pharmaceutical companies, such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners., and Asubio Pharma.

History

BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.

Best performing analysts who are covering BMRN - Biomarin Pharmaceutical:

Eliana Merle Alethia Young Edward Nash Cory Kasimov Michael Ulz Salveen Richter

Currently out of the existing stock ratings of BMRN, 9 are a HOLD (21.95%), 32 are a BUY (78.05%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 10-Jan-2022

$105

$38.47 (57.82%)

$110

10 days ago
(31-Aug-2026)

3/10 (30%)

$39.77 (60.97%)

269

Buy Since 19-Aug-2026

$98

$31.47 (47.30%)

$82

22 days ago
(19-Aug-2026)

4/11 (36.36%)

$28.67 (41.35%)

105

Buy Since 20-Jan-2016

$111

$44.47 (66.84%)

$105

24 days ago
(17-Aug-2026)

7/16 (43.75%)

$44.36 (66.57%)

584

Buy Since 26-Feb-2026

$114

$47.47 (71.35%)

$111

1 months ago
(10-Aug-2026)

5/15 (33.33%)

$45.12 (65.51%)

41

Buy Since 21-Apr-2025

$97

$30.47 (45.80%)

$95

1 months 3 days ago
(07-Aug-2026)

14/19 (73.68%)

$33.19 (52.01%)

79

Show more analysts

Please expand the browser size to see the chart

What is BMRN (Biomarin Pharmaceutical) average time for price targets to be met?

On average it took 345 days for the stock forecasts to be reached, with an average price target met ratio of 45.95%.

Which analyst most recently updated their price target on BMRN (Biomarin Pharmaceutical)?

Akash Tewari

Which analyst has the most public recommendations on BMRN (Biomarin Pharmaceutical)?

Akash Tewari works at JEFFERIES and has 9 price targets and 5 ratings on BMRN

Which analyst is the currently most bullish on BMRN (Biomarin Pharmaceutical)?

Ying Huang with the highest potential upside of $110.47

Which analyst is the currently most reserved on BMRN (Biomarin Pharmaceutical)?

Mitchell Kapoor with the lowest potential downside of -$11.53

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?